Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
The paper introduces three interconnected resources for the global scientific community: * LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology; * Longevity-LLMs, a family of compact, open-source language models specif...
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden ...
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths
CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital Internatio...
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inh...
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-spec...
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
* FDA Fast Track Designation (FTD)
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass...
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-s...
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI),and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical ...
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The s...
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,...
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration wit...
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
Cambridge, Mass., May 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly launched company established by Human Longevity, Inc. today announc...
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a ...
Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. * The inhalation solution is designed for targeted lung delivery...
